Page 24 - Read Online

Page 216 Wu et al. Cancer Drug Resist 2018;1:204-18 I http://dx.doi.org/10.20517/cdr.2018.16

cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33.
23. Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, et al. Intracellular released payload influences potency and bystander-killing
effects of antibody-drug conjugates in pre-clinical models. Cancer Res 2016;76:2710-9.
24. Cortes J, Dieras V, Lorenzen S, Montemurro F, Riera-Knorrenschild J, et al. Abstract CT096: trastuzumab emtansine (T-DM1) +
capecitabine in HER2-positive metastatic breast cancer (mBC) and HER2-positive locally advanced (LA)/metastatic gastric cancer
(mGC): results from the phase I/randomized phase II TRAXHER2 study. Cancer Res 2018;78:CT096.
25. Gelmon KA, Vidal M, Sablin MP, Serpanchy R, Soberino J, et al. Trastuzumab emtansine (T-DM1) plus capecitabine (X) in patients
with HER2-positive MBC: MO28230 TRAX-HER2 phase 1 results. J Clin Oncol 2014;32:606.
26. Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, et al. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I
inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 2016;22:5097-108.
27. Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, et al. DS-8201a, a new HER2-targeting antibody-drug conjugate
incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer
2017;141:1682-9.
28. Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth
factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci
2016;107:1039-46.
29. Tamura K, Shitara K, Naito Y, Shimomura A, Fujiwara Y, et al. Single agent activity of DS-8201a, a HER2-targeting antibody-drug
conjugate, in breast cancer patients previously treated with T-DM1: phase 1 dose escalation. Ann Oncol 2016;27:LBA17.
30. Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan
(DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a
phase 1 dose-escalation study. Lancet Oncol 2017;18:1512-22.
31. Iwasa S, Shitara K, Takahashi S, Park H, Kadowaki S, et al. Updated results of phase 1 study of DS-8201a in subjects with HER2-
expressing gastric cancer. J Clin Oncol 2018;36:118.
32. Tsurutani J, Doi T, Iwata H, Takahashi S, Modi S, et al. 409PUpdated results of phase 1 study of DS-8201a in patients with HER2
expressing non-breast, non-gastric malignancies. Ann Oncol 2017;28:mdx367.042.
33. Bergstrom DA, Bodyak N, Park PU, Yurkovetskiy A, DeVit M, et al. Abstract P4-14-28: XMT-1522 induces tumor regressions in pre-
clinical models representing HER2-positive and HER2 low-expressing breast cancer. Cancer Res 2016; doi: 10.1158/1538-7445.
34. Bergstrom DA, Bodyak N, Yurkovetskiy A, Park PU, DeVit M, et al. Abstract LB-231: a novel, highly potent HER2-targeted antibody-
drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-
driven tumors. Cancer Res 2015; doi: 10.1158/1538-7445.
35. Hamilton EP, Barve MA, Bardia A, Beeram M, Bendell JC, et al. Phase 1 dose escalation of XMT-1522, a novel HER2-targeting
antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors. J Clin Oncol 2018; doi:
10.1200/JCO.2018.36.15_suppl.2546.
36. Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, et al. A Biparatopic HER2-targeting antibody-drug conjugate induces tumor
regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell 2016;29:117-29.
37. Pegram M, Hamilton E, Tan AR, Storniolo AM, Elgeioushi N, et al. 47O Phase 1 study of bispecific HER2 antibody-drug conjugate
MEDI4276 in patients with advanced HER2-positive breast or gastric cancer. Ann Oncol 2018;29:iii7-9.
38. Verheijden G, Beusker P, Ubink R, van der Lee M, Groothuis P, et al. Toward clinical development of SYD985, a novel HER2-targeting
antibody-drug conjugate (ADC). J Clin Oncol 2014;32:626.
39. van der Lee MM, Groothuis PG, Ubink R, van der Vleuten MA, van Achterberg TA, et al. The preclinical profile of the duocarmycin-
based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers. Mol Cancer Ther
2015;14:692-703.
40. Black JD, Lopez S, Cocco E, Bellone S, Bonazzoli E, et al. Abstract 2461: SYD985, a novel HER2-targeting antibody-drug conjugate,
shows strong antitumor activity in primary USC cell lines with low (1+) and moderate (2+) HER2/Neu expression. Cancer Res
2015;75:2461.
41. Dokter WHA, van der Lee M, Groothuis P, van Achterberg T, Loosveld E, et al. Abstract 2652: In vitro and in vivo antitumor activity of
SYD985, a novel HER2-targeting ADC: a comparison with T-DM1. Cancer Res 2014;74:2652.
42. Saura C, Thistlethwaite F, Banerji U, Lord S, Moreno V, et al. A phase I expansion cohorts study of SYD985 in heavily pretreated
patients with HER2-positive or HER2-low metastatic breast cancer. J Clin Oncol 2018;36:1014.
43. Humphreys RC, Kirtely J, Hewit A, Biroc S, Knudsen N, et al. Abstract 639: site specific conjugation of ARX-788, an antibody drug
conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers. Cancer Res 2015;75:639.
44. Zammarchi F, Reinert HW, Janghra N, Corbett S, Mellinas-Gomez M, et al. Abstract 52: mechanistic and benchmarking studies of
ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors.
Cancer Res 2017;77:52.
45. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, et al. Mesothelin is overexpressed in the vast majority of ductal
adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin
Cancer Res 2001;7:3862-8.
46. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008;44:46-53.
47. Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, et al. Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol
2016;34:4171-9.
48. NIH. An efficacy study of MORAb-009 in subjects with pancreatic cancer. Available from: https://ClinicalTrials.gov/show/